What's Happening?
Otsuka Pharmaceutical has announced positive interim results from its Phase 3 VISIONARY trial, demonstrating that VOYXACT (sibeprenlimab-szsi) preserved kidney function in patients with IgA nephropathy
over 12 months. The trial showed a mean eGFR change from baseline of +0.7 mL/min/1.73 m² compared to a decline in the placebo group, indicating a treatment effect of 5.5 mL/min/1.73 m². VOYXACT is the first FDA-approved selective APRIL inhibitor, targeting key drivers of disease progression. Otsuka has initiated a rolling submission for a supplemental Biologics License Application to the FDA for traditional approval based on 24-month data.
Why It's Important?
The interim results from the VISIONARY trial highlight VOYXACT's potential as a targeted therapy for IgA nephropathy, a chronic kidney disease with limited treatment options. By preserving kidney function, VOYXACT could improve long-term outcomes for patients, reducing the risk of kidney failure and the need for dialysis or transplant. For Otsuka, the successful development and approval of VOYXACT could enhance its nephrology portfolio and strengthen its position in the market. The trial results also support the therapeutic approach of selective APRIL inhibition, which may offer a safer and more effective treatment option for patients.
